ライフスタイルドラッグ（生活改善薬）市場見通し

The market for lifestyle drugs has become one of the most dynamic and commercially attractive sectors in the pharmaceutical industry. With developed markets expected to witness aging demographics as well as continued increases in health awareness, disposable incomes and pharmaceutical branding activity, conditions appear highly favourable for further growth. ‘Lifestyle Drugs Market Outlook' is a new report published by Business Insights that provides a detailed analysis of seven individual lifestyle drug markets through the stages of drug delivery and discovery to product launch and lifecycle management. Key industrial trends in the fields of consumer demand and pipeline development are examined, leading players and products within each treatment area are profiled and the market potential of each lifestyle therapy is assessed. This report will also provide a substantial review of reimbursement policies within the seven major markets and their impact upon product sales.

Table of Contents

• Introduction
• Alcohol Dependence
• Alopecia
• Obesity
• Oral Contraception
• Sexual Dysfunction
• Skin Aging
• Smoking Cessation

• Summary
• Introduction
• Defining the Market
• Defining Lifestyle Conditions
• Social Characteristics
• Disease characteristics
• Product Characteristics

• Sales Potential
• High demand upon launch
• Ability to create new markets

• Drivers of demand for lifestyle drugs
• An aging population
• Growth in disposable income
• Increasing consumer awareness
• Rise in branding activities

• Barriers to market growth
• Demonstrating favorable health economics to payors - the road to rationing
• Drug abuse and misuse
• Loss of corporate control over brand

• Reimbursement
• Recommendations for securing reimbursement of lifestyle drugs
• Data Caveats

• Summary
• Overview of Alcohol Dependence
• Diagnosis
• Measuring & Diagnosing
• Pathophysiology
• Factors Influencing Severity of Symptoms
• Gender Influence
• Genetic Influence
• Prevalence
• Reimbursement

• Drug Therapy
• Disulfiram (Aldehyde Dehydrogenase Inhibitor)
• Naltrexone
• Benzodiazepines
• Sodium Oxybate
• Acamprosate
• Metadoxine

• Market Analysis
• Campral (Acamprosate)
• Antabuse
• Naltrexone Therapies
• Pipeline Outlook

• Summary
• Overview of Alopecia
• Pathophysiology & Etiology
• Alopecia areata
• Androgenetic alopecia
• Anagen effluvium
• Telogen effluvium
• Scarring alopecia
• Self-induced alopecia
• Other causes

• Prevalence
• Drug Therapy
• Market Analysis
• Propecia
• Rogaine (minoxidil)
• Pipeline Outlook

• Summary
• Overview of Obesity
• Definition
• Measuring & Diagnosing Obesity
• Pathophysiology & etiology
• Factors influencing severity of Obesity
• Age and Gender Influence
• Genetic Influence
• Nutritional Influence
• Prevalence
• Reimbursement
• Drug Therapy
• Market Analysis
• Xenical
• Reductil/Meridia/Ectiva (sibutramine)
• Acomplia (Rimobant)
• Company Analysis
• Pipeline Outlook
• Novel Mechanisms

• Summary
• Overview of Oral Contraception
• The female reproductive population
• Drug therapy
• Side Effect Profile

• Market Analysis
• The Yasmin Franchise
• Ortho Tri-cyclen Lo
• Estrostep Fe
• Ortho Evra
• Mirena
• Seasonale
• Reimbursement
• Promotional Spend
• Company Analysis
• Pipeline Outlook

• Summary
• Overview of Sexual Dysfunction
• Male Sexual Dysfunction
• Diagnosis
• Pathophysiology & diagnostic indicators
• Erectile dysfunction (ED)
• Loss of libido
• Priapism
• Peyronie' s disease
• Premature and delayed ejaculation
• Contributing Factors
• Prevalence
• Reimbursement
• Drug Therapy
• PDE-5 Inhibitors
• Alprostadil

• Market Analysis
• Viagra
• Cialis
• Levitra

• Promotional Spend
• Product Pipeline
• Delivery Mechanism
• Niche Markets
• OTC Retail
• Phosphodiesterase Inhibitors

• Female sexual Dysfunction
• Diagnosis
• Sexual desire disorders
• Female sexual arousal disorder
• Sexual orgasmic disorder
• Sexual pain disorders

• Measuring & diagnosing
• Factors influencing the severity of female sexual dysfunction
• Genetic Influence
• Prevalence
• Drug Therapy
• Pipeline outlook

• Summary
• Overview of Skin Aging
• Pathophysiology and etiology
• Factors Driving Demand
• Demographic Influence
• Personal Appearance Gain
• Acceptance of Cosmetic Procedures

• Prevalence
• Drug Therapy
• Market Analysis
• Renova (tretinoin)
• Retin-A/Retin-A Micro (tretinoin)
• Botox (botulinum toxin type A)
• Tazarotene
• Company Activities
• Product Pipeline

• Summary
• Overview of smoking cessation
• Measuring & Diagnosing
• Pathophysiology & etiology
• Factors influencing smoking cessation
• Prevalence
• Policy & Reimbursement
• Drug Therapy
• Nicotine replacement therapy
• Antidepressants
• Nicotine partial receptor agonists

• Market Analysis
• Champix/Chantix (US)
• Nicotine Replacement Therapies
• Zyban
• Promotional Spend
• Company Analysis
• Pipeline Outlook
• Opioid Receptor Agonists
• Cannabinoid Receptor Antagonists
• Clonidine
• Nicotine Conjugate Vaccine
• Glycine Receptor Antagonist

• IMS data
  • Alcohol Dependence
  • Alopecia
  • Obesity
  • Oral Contraception
  • Sexual Dysfunction
  • Smoking Cessation
• Pearl Index
• Index

• Figure 1.1: Defining Lifestyle Drugs
• Figure 1.2: The reimbursement decision process
• Figure 1.3: Improving reimbursement status of lifestyle drugs: a three-pronged approach
• Figure 2.4: Geographic market shares for Alcohol Dependence Drugs by sales revenue, 2006 ($m)
• Figure 2.5: Pipeline for alcohol dependence therapies, 2007
• Figure 3.6: Pipeline for alopecia therapies, 2007
• Figure 4.7: Geographic market shares for anti-obesity products by sales revenue, 2006 ($m)
• Figure 4.8: Pipeline for obesity therapies, 2007
• Figure 5.9: Revenues by drug class for prescription oral contraceptives ($m), 2006; EU5, Japan, USA
• Figure 5.10: Geographic market sizes for prescription oral contraceptives by sales revenue, 2006 ($m)
• Figure 5.11: Promotional spend on top oral contraceptive brands in major markets (EU5, USA), 2006 ($m)
• Figure 5.12: Pipeline for oral contraceptives, 2007
• Figure 6.13: Geographic market size for erectile dysfunction products by sales revenue, 2006,($m)
• Figure 6.14: Pipeline for erectile dysfunction therapies, 2007
• Figure 6.15: Possible caused of female sexual dysfunction
• Figure 6.16: Pipeline for female sexual dysfunction therapies, 2007
• Figure 7.17: Factors influencing cosmeceutical consumption across the major markets
• Figure 7.18: Demographics of skin aging concerns
• Figure 7.19: Pipeline for skin aging therapies, 2007
• Figure 8.20: Global sales of smoking cessation drugs, 2006 ($m)
• Figure 8.21: Pipeline for smoking cessation products, 2007

• Table 1.1: Distribution channels covered in IMS MIDAS database
• Table 2.2: Top 10 Alcohol dependency therapies 2007, Growth Metrics
• Table 2.3: Pipeline analysis; alcohol dependence therapies
• Table 3.4: Drug therapy for common types of alopecia
• Table 3.5: Top 10 alopecia brands 2007, growth metrics
• Table 4.6: Classification of overweight, obesity by BMI, waist circumference and associated disease risk
• Table 4.7: Obesity-linked Genotypes
• Table 4.8: Projected prevalence of obesity, 2006-2012 (' 000s)
• Table 4.9: Top 10 anti-obesity brands 2007, growth metrics
• Table 4.10: Obesity pipeline products
• Table 5.11: Forecast growth of the childbearing population; EU5, US and Japan, 2007-10 (000s)
• Table 5.12: Top 10 oral contraceptive brands, 2007 ($m)
• Table 6.13: Common physiological causes of erectile dysfunction
• Table 6.14: Prevalence of moderate and severe ED in the seven major markets
• Table 6.15: Top 5 erectile dysfunction brands 2007; growth metrics
• Table 6.16: Pipeline analysis; female sexual dysfunction (FSD)
• Table 7.17: Symptoms of skin aging
• Table 8.18: Factors influencing smoking cessation success
• Table 8.19: Smoking prevalence; EU5, US, Japan; 2002
• Table 8.20: Top 10 smoking cessation brands 2007, growth metrics